home / stock / atra / atra quote
Last: | $0.61 |
---|---|
Change Percent: | 0.6% |
Open: | $0.6 |
Close: | $0.61 |
High: | $0.6349 |
Low: | $0.585602 |
Volume: | 1,823,190 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.61 | $0.6 | $0.61 | $0.6349 | $0.585602 | 1,823,190 | 05-17-2024 |
$0.6036 | $0.6327 | $0.6036 | $0.6599 | $0.5963 | 1,126,284 | 05-16-2024 |
$0.64 | $0.6 | $0.64 | $0.67 | $0.6 | 991,911 | 05-15-2024 |
$0.605 | $0.56 | $0.605 | $0.6179 | $0.5564 | 1,416,902 | 05-14-2024 |
$0.5564 | $0.5406 | $0.5564 | $0.5637 | $0.4843 | 2,535,373 | 05-13-2024 |
$0.5299 | $0.57 | $0.5299 | $0.6283 | $0.525 | 2,057,755 | 05-10-2024 |
$0.5458 | $0.57 | $0.5458 | $0.579702 | $0.537 | 1,751,363 | 05-09-2024 |
$0.5655 | $0.5977 | $0.5655 | $0.6063 | $0.56 | 1,437,054 | 05-08-2024 |
$0.6026 | $0.64 | $0.6026 | $0.6499 | $0.579 | 1,664,665 | 05-07-2024 |
$0.6298 | $0.675 | $0.6298 | $0.6966 | $0.61 | 1,142,896 | 05-06-2024 |
$0.67 | $0.6501 | $0.67 | $0.6849 | $0.65 | 741,816 | 05-03-2024 |
$0.6503 | $0.7 | $0.6503 | $0.7062 | $0.61 | 2,214,549 | 05-02-2024 |
$0.6845 | $0.7065 | $0.6845 | $0.76 | $0.6845 | 1,117,399 | 05-01-2024 |
$0.69 | $0.7 | $0.69 | $0.7322 | $0.69 | 707,756 | 04-30-2024 |
$0.7142 | $0.69 | $0.7142 | $0.7393 | $0.6601 | 999,999 | 04-29-2024 |
$0.69 | $0.69 | $0.69 | $0.7099 | $0.68 | 526,741 | 04-26-2024 |
$0.6998 | $0.72 | $0.6998 | $0.72 | $0.66 | 866,587 | 04-25-2024 |
$0.7147 | $0.7211 | $0.7147 | $0.7366 | $0.69 | 697,941 | 04-24-2024 |
$0.7186 | $0.6884 | $0.7186 | $0.7243 | $0.6664 | 833,224 | 04-23-2024 |
$0.6974 | $0.6674 | $0.6974 | $0.7053 | $0.6632 | 856,889 | 04-22-2024 |
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Tab-cel ® U.S. BLA on Track for Submission in Q2 2024 Initiation of ATA3219 Lupus Nephritis Study Expected in Q4 2024, with Initial Clinical Data Expected in H1 2025 Initiation of New ATA3219 Cohort Without Lymphodepletion in Severe Systemic Lupus Erythematosus Planned fo...
Tab-cel ® U.S. BLA on Track for Submission in Q2 2024 Following Positive Pre-BLA Meeting Allogeneic CAR T Pipeline Expands Into Autoimmune Disease With Plans to Initiate an ATA3219 Lupus Nephritis Study in H2 2024, and Initial Clinical Data Expected H1 2025 AT...